title: Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients.
abstract: To identify CTL-directed antigens in gastrointestinal cancer, we have investigated antigens recognized by the HLA-A2-restricted CTL line established from T cells infiltrating into colon cancer and report herein cleavage and polyadenylation specificity factor (CPSF) as a potent antigen holding peptides capable of inducing CTLs. Five peptides at amino acid positions 250-258, 392-400, 534-542, 1296-1304 and 1359-1368 of CPSF, which were recognized by the CTL line, were found to have the ability to induce HLA-A2-restricted and tumor-specific CTLs in peripheral blood mononuclear cells of the majority (69%, 11/16) of gastrointestinal cancer patients with different HLA-A2 subtypes. Thus, these peptides might be appropriate molecules for use in the peptide-based specific immunotherapy of HLA-A2(+) patients with gastrointestinal cancers.
authors: Department of Immunology, Kurume University School of Medicine, Kurume, Japan.
authors: Yoshiaki
authors: Y
authors: Maeda
authors: Masaaki
authors: M
authors: Ito
authors: Nanae
authors: N
authors: Harashima
authors: Tetsuya
authors: T
authors: Nakatsura
authors: Naoya
authors: N
authors: Hida
authors: Nobue
authors: N
authors: Imai
authors: Yuuji
authors: Y
authors: Sato
authors: Shigeki
authors: S
authors: Shichijo
authors: Satoru
authors: S
authors: Todo
authors: Kyogo
authors: K
authors: Itoh
mesh_terms: D000595:Amino Acid Sequence; D015152:Blotting, Northern; D019496:Cancer Vaccines; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005770:Gastrointestinal Neoplasms / Q000378:metabolism*; D015789:HLA-A2 Antigen / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry; D016601:RNA-Binding Proteins / Q000096:biosynthesis*; D012685:Sepharose / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D039221:mRNA Cleavage and Polyadenylation Factors
chemical_list: D019496:Cancer Vaccines; D018076:DNA, Complementary; D015789:HLA-A2 Antigen; D007376:Interleukin-2; D010455:Peptides; D016601:RNA-Binding Proteins; D039221:mRNA Cleavage and Polyadenylation Factors; D007371:Interferon-gamma; D012685:Sepharose